Business Areas
Improving the quality of our lives through state-of-the-art R&D capabilities.
Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem’s new growth engine in the mid to long term.
We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.
Sales
Life Science Sales Graph Business Areas LG Chem Life Science Sales Graph Business Areas LG Chem
Sales :2022 ,2023 ,2024
2022 0.9
2023 1.2
2024 1.3

Unit : KRW trillion

  • 2024 Technology export of rare obesity drug to U.S. company 'Rhythm Pharmaceuticals'
  • 2023 Acquired AVEO, a US-based cancer drug company
  • 2022 Applied for global Phase lll clinical trial for Tigulixostat(new dug for gout) with the US
  • 2021 Established a joint venture sales corporation LG Jiansheng Life Sciences in ChinaSucceeded in phase II clinical trial of the new gout drug in the US
  • 2019 Established the Global Innovation Center in Boston, US
  • 2017 Merged with
    LG Life Sciences
  • 2012 Released the first Korean diabetes drug Zemiglo
  • 2003 1st Korean NCE approved by
    USA FDA(Factive)
  • 1996 Won the first prequalification by the WHO with Hepatitis B vaccine Euvax B
  • 1991 Developed World’s first
    4th generation Cephalosporin
  • 1984 Established Pharmaceuticals
    business division
  • 1961 Obtained the drug manufacturing permit
Division
Primary Care Division Business Areas LG Chem Primary Care Division
Specialty Care Division Business Areas LG Chem Specialty Care Division
Aesthetic Division Business Areas LG Chem Aesthetic Division
Go to the related products ▶
VISION

Toward a World-Class Innovative Drug Developer

  • 5 or more innovative new drugs by 2030
  • Enhanced the quality of new drug pipeline
  • Invest over USD 250mil in annual R&D
  • Strengthening of Open innovation
  • Diabetes, metabolic diseases, cancer, autoimmune diseases
  • Expand new drug pipelines in clinical development stage
  • Expand new drug pipelines in clinical development stage :2024 ,2030
    2024 12EA
    2030 20EA

    Explore Research Preclinical Clinical

  • Accelerate clinical developments and business growth worldwide
  • New tasks for global clinical development
  • Continued growth of AVEO's oncology business in the US
LG Chem Life Science Pipeline

  • Diabetes & Metabolism
  • Oncology & Immunology
  • Cell Therapy
  • Vaccine
  • Aesthetic
  1. Preclinical(4)
    • LR19023 LR19023Oncology
      LR19023
      해당 프로젝트 팝업
      Molecule LR19023
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
    • LR19128 LR19128Oncology
      LR19128
      해당 프로젝트 팝업
      Molecule LR19128
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner Avactar Life sciences

      Affimer® Technology

    • LR20061 LR20061Atopic Dermatitis
      LR20061
      해당 프로젝트 팝업
      Molecule LR20061
      Stage Preclinical
      Indication Atopic Dermatitis
      Modality Chemical
      Target Undisclosed
    • LR19157 LR19157Oncology
      LR19157
      해당 프로젝트 팝업
      Molecule LR19157
      Stage Preclinical
      Indication Oncology
      Modality Chemical
      Target Undisclosed
  2. Phase I(8)
    • LR19129 CUE-102Oncology
      LR19129
      해당 프로젝트 팝업
      Molecule CUE-102
      Stage Phase 1 (by Partner)
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target WT-1
      Partner Cue Biopharma
    • LR19127 CUE-101HNSCC
      LR19127
      해당 프로젝트 팝업
      Molecule CUE-101
      Stage Phase 1 (by Partner)
      Location summary USA
      Indication HNSCC
      Modality Biologics
      Target HPV
      Partner Cue Biopharma
    • LR19125 PDC*LungNSCLC
      LR19125
      해당 프로젝트 팝업
      Molecule PDC*Lung
      Stage Phase 1 (by Partner)
      Location summary Europe
      Indication NSCLC
      Modality Cell therapy
      Target Cancer vaccine
      Partner PDC*line Pharma
    • LR20011 GEN-001Solid tumor
      LR20011
      해당 프로젝트 팝업
      Molecule GEN-001
      Stage Phase 1 (by Partner)
      Location summary USA
      Indication Solid tumor
      Modality Microbiome
      Target Microbiome
      Partner Genome & Company
    • AV-380 AV-380Cachexia
      AV-380
      해당 프로젝트 팝업
      Molecule AV-380
      Stage Preclinical
      Location summary USA
      Indication Cachexia
      Modality Biologics
      Target anti-GDF15 IgG1 mAb
    • AV-203 AV-203Oncology
      AV-203
      해당 프로젝트 팝업
      Molecule AV-203
      Stage Phase 1
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target Anti-ERBB3 IgG1 mAb
    • LR19155 LR19155Oncology
      LR19155
      해당 프로젝트 팝업
      Molecule LR19155
      Stage Phase 1
      Indication Oncology
      Modality Biologics
      Target LILRB1
    • LR19018 LG203003NASH
      LR19018
      해당 프로젝트 팝업
      Molecule LG203003
      Stage Phase 1
      Location summary USA
      Indication NASH
      Modality NCE
      Target DGAT-2
  3. Phase II(5)
    • LR20062 aP vaccine
      LR20062
      해당 프로젝트 팝업
      Molecule aP vaccine
      Stage Phase 2
      Indication aP vaccine
      Modality Vaccine
      Target aP vaccine

      Diphtheria, Tetanus, Pertussis,Polio, Hib, HebB

    • LR19021 LB54640Genetic Obesity
      LR19021
      해당 프로젝트 팝업
      Molecule LB54640
      Stage Phase 2
      Location summary USA
      Indication Genetic Obesity
      Modality NCE
      Target MC4R
    • LR19114 6 in 1 Vaccine
      LR19114
      해당 프로젝트 팝업
      Molecule 6 in 1 Vaccine
      Stage Phase 2
      Indication 6 in 1 Vaccine
      Modality Vaccine
      Target 6 in 1 Vaccine

      Diphtheriae (D), Bordetella pertussis (wP), Clostridium tetani (T), Hepatitis B (HepB) Haemophilus influenzae type b(Hib) Vaccine-Associated Paralytic Poliomyelitis(IPV)

    • LR19019 ZectivimodUlcerative colitis Atopic dermatitis
      LR19019
      해당 프로젝트 팝업
      Molecule Zectivimod
      Stage Phase 2 (by Partner)
      Location summary China
      Indication Ulcerative colitis Atopic dermatitis
      Modality NCE
      Target S1P1
      Partner TransThera (License-out)

      License-out, China

    • LR19024 LG34053Osteoarthritis
      LR19024
      해당 프로젝트 팝업
      Molecule LG34053
      Stage Phase 1b/2
      Location summary Republic of Korea
      Indication Osteoarthritis
      Modality NCE
      Target Undisclosed
  4. Phase III(2)
  5. NDA(2)
    • LR20024 Y-solution, MDRHA filler
      LR20024
      해당 프로젝트 팝업
      Molecule Y-solution, MDR
      Stage NDA
      Location summary Europe
      Indication HA filler
      Modality HA
      Target HA
    • LR19094 Y-solution, ChinaHA filler
      LR19094
      해당 프로젝트 팝업
      Molecule Y-solution, China
      Stage NDA
      Location summary China
      Indication HA filler
      Modality HA
      Target HA
Image Download 다운로드
Core Products
Eutropin Business Areas LG Chem Eutropin
Hyruan One Business Areas LG Chem Hyruan One
Zemiglo / Zemimet SR Tab. / Zemidapa Business Areas LG Chem Zemiglo / Zemimet SR Tab. / Zemidapa
Eucept Business Areas LG Chem Eucept
YVOIRE Business Areas LG Chem YVOIRE
Press Releases
LG Chem Becomes First Korean Company to Enter Canadian Dermal Filler Market 2024.12.12
LG Chem Becomes First Korean Company to Enter Canadian Dermal Filler Market 2024.12.12
LG Chem Successfully Concludes FAME Global 2024 Symposium on Global Infertility and Reproductive Medicine 2024.08.08
more
Video
Select Opening of a Global Innovation Center Opening of a Global Innovation Center